RxDoctor Payments Data

Susan Wellborn

Family · Long Beach, CANPI 1578699484

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 73.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $5,234 and has fallen 97.2% since, to $148 in 2024. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,901in general payments, 2019–2025

Across 185 payments — averaging $42.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$999
  • Johnson & Johnson$304
  • EMD Serono, Inc.$170
  • Napo Pharmaceuticals Inc$155
  • AbbVie$154
  • plus $287 from 5 others

What the payments were for

  • Consulting fees$3,60046%
  • Speaking & faculty fees$330%
  • Travel & lodging$5197%
  • Food & beverage$3,73847%
  • Education$110%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,901 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala57$215,987
CabenuvaCabotegravir/Rilpivirine22$127,233
DovatoDolutegravir Sodium/Lamivudine34$99,597
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$55,126
TivicayDolutegravir Sodium26$54,589
PrezcobixDarunavir/Cobicistat18$40,594
Atazanavir Sulfate11$2,125
Albuterol Sulfate HfaAlbuterol Sulfate27$973
Testosterone Cypionate17$503
Gabapentin32$359
Atorvastatin Calcium53$341
Tamsulosin Hcl35$243
Trazodone Hcl27$232
Rosuvastatin Calcium32$176
Ibuprofen14$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyCabenuva, Dovato, Tivicay$5,831$281,42082 claims
GileadBiktarvy$999$215,98757 claims
Johnson & JohnsonPrezcobix$304$40,59418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Long Beach

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →